



The  
Patent  
Office

PCT/EP

EP 0 0 1 9 4

0 0 / 0 2 1 9 4



27. 06. 2000 INVESTOR IN PEOPLE

(61)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

EP 0 0 1 9 4

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 07 JUL 2000

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

*AmBrewster*

Dated 29 February 2000

**THIS PAGE BLANK (USPTO)**

## Patents Form 1/77

Patents Act 1977  
(Rule 16)

The  
Patent  
Office

9 E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

E432194-1 D10011

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road

Newport

Gwent NP9 1RH

## 1. Your reference

CV-0290 GB

## 2. Patent application number

(The Patent Office will fill in this part)

9905663.2

## 3. Full name, address and postcode of the or of each applicant (underline all surnames)

Bristol-Myers Squibb Company  
345 Park Avenue  
New York  
New York 10154  
United States of America

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

Delaware, USA

4448882001

## 4. Title of the invention

Iodine Preparation Composition

## 5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Julie MAYS  
Bristol-Myers Company Limited  
Patent Department  
Swakeleys House, Milton Road  
Ickenham  
Uxbridge UB10 8NS  
United Kingdom

Patents ADP number (if you know it)

73740

6877328001

## 6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)Date of filing  
(day / month / year)

## 7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

## 8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

7

Claim(s)

1

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

1

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/we request the grant of a patent on the basis of this application.

Signature

Julie Mays

Date

12 Mar 99

12. Name and daytime telephone number of person to contact in the United Kingdom

Julie MAYS 01895 628209

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

DUPLICATE

CV0290

-1-

## Iodine Preparation Composition

This invention relates to an antimicrobial composition which can be applied to wounds, cuts, abrasions or burns for the prevention or treatment of infections.

5 More particularly the invention relates to a composition capable of providing effective antimicrobial activity while at the same time avoiding wound and skin irritation and retardation of wound healing.

10 Topical antimicrobial materials and preparations containing them have long been recognised as important parts of antiseptics of intact skin and wounds. Iodine has been recognized as an antimicrobial agent with effectiveness against a wide range of micro-organisms. There are however several barriers to making an effective antimicrobial composition for application to wounds based on iodine. One problem is that iodine tends to react with organic materials found in the wound  
15 other than the intended microbial targets. This means that to be effective, iodine needs to be included at high levels such as 0.9% by weight, as described in "Handbook of Wound Dressings" edited by Stephen Thomas, 1994 Journal of Wound Care. . At such levels and with continued use iodine may have undesirable local side effects such as cell toxicity, hypersensitivity reactions, skin  
20 staining, and unpleasant odour and systemic adverse effects such as metabolic acidosis and impairment of renal function. For this reason application of iodine is recommended at levels below 1.35g in one week.

CV0290

-2-

A further problem is that iodine has a relatively short shelf life when in aqueous solution meaning either that compositions which include water need to be freshly prepared before each application or again that iodine is included at high levels. These factors limit product form.

5

In the past these problems with iodine have sought to be addressed by the use of iodophors which act as a release mechanism for iodine. Iodophors are readily dissociable, loose complexes of iodine with polymers or surfactants. Iodophor compositions are not best suited to use on wounds because when applied to a wound, all iodine present in the composition is readily available for reaction and therefore the adverse reactions associated with high levels of iodine are not necessarily avoided.

10

There thus exists a need for a composition which delivers iodine to a wound at a rate which is high enough to provide effective antisepsis but which is low enough to avoid the problems of adverse reactions associated with high levels of iodine.

15

GB-B-2276546 to Diversey relates to improved iodophors which are prepared at the point of use. The composition comprises an iodide source, an oxidant and an acid source, the oxidant becoming active only when the composition is dissolved in an aqueous medium. The composition is said to overcome the stability problems associated with producing teat dip/spray iodine formulations for use in

20

CV0290

-3-

the control of bovine mastitis. The rate of generation of iodine needed for these topical formulations for use on intact skin far exceeds that tolerable to a wound. In these compositions such high levels of iodine are generated that a hydrotrope must be included to prevent the iodine from crystallising. In addition, iodine has a complex chemistry in aqueous solutions and exists in a number of equilibria. At high iodine concentrations in the presence of iodide there is a strong tendency for the tri-iodide ion to form. We believe that this ion has very little antimicrobial activity but can still be absorbed with the risk of systemic toxicity.

We have found that it is possible to prepare a composition which is capable of generating iodine at a rate and level that makes it suitable for use in wounds. This is achieved by separating certain of the ingredients and controlling the kinetics of the generation of iodine through the manipulation of pH.

Accordingly the present invention provides an iodine preparation composition suitable for use on wounds comprising an iodide source, an oxidant and a buffer characterised in that the oxidant is held separately from the iodide until the point of use, and that the buffer is capable of maintaining the pH of the composition at between pH 4.5 and pH 6 so that iodine is generated at a physiologically acceptable and efficacious rate.

The invention allows the preparation of compositions generating a low but effective iodine level for example up to about 2000 $\mu$ g per g of composition per

CV0290

-4-

hour, preferably in the range of 5 $\mu$ g per g of composition per hour to 1500 $\mu$ g per g of composition per hour, more preferably in the range 50 $\mu$ g per g of composition per hour to 1000 $\mu$ g per g of composition per hour so that the amount of free iodine available for antiseptis at any time is at least 0.001%.

5

The compositions of the invention are preferably formulated to generate the above levels of iodine over a period of about 3 days.

10

The pH of the composition of the invention is generally below 5.8. We have found that if the pH is greater than about 6, the rate of production of iodine by reaction of the oxidising agent with iodide ions is too low to balance any losses of iodine by reaction with the organic matter. We have found that it is generally desired that the pH of the compositions is not below about 4.5 as otherwise there is a danger that the rate of oxidation of the iodide ions will be too fast with the result that the composition could become toxic.

15

20

The desired pH of the compositions may be achieved by incorporating buffering agents therein. Examples of buffering agents which may be included are citric acid/disodium hydrogen phosphate, citric acid/sodium citrate, acetic acid/sodium acetate. The buffering agent may conveniently be present in an amount of about 2% to 10%, preferably about 4% to 6% by weight and particularly about 5% by weight so as to provide an isotonic composition.



CV0290

-5-

The amount of oxidant in the composition is tailored to provide a stoichiometric match with iodide. Preferably the oxidant is iodate and is provided in a molar ratio of 1:5 with iodide. In this way the iodide present in the composition fully reacts with all the oxidant. To provide the levels and rate of production of iodine in the range described above it is desirable to include up to 2% by weight of iodide, preferably, from 0.2 % to 2 % by weight of iodide. Iodide and iodate are preferably present as sodium salts although other usual counter ions may be used.

Convenient forms of administration of the composition include aqueous gels, films, creams, tablets and capsules.

The following examples are illustrative of the present invention.

Example 1.

<u>Gel A</u>	<u>Weight g</u>
Hydroxyethyl cellulose	30.00
Propylene Glycol	150.00
Na <sub>2</sub> HPO <sub>4</sub>	35.61
Citric Acid	21.01
Potassium Iodate	1.124
Water	762.256

Gel BWeight in g

CV0290

-6-

Hydroxyethyl cellulose	30.0
Propylene Glycol	150.0
Potassium Iodide	4.36
Water	815.64

5

10

Gel A was made by dissolving the buffer salt in a water/propylene glycol mix and then adding the iodate. When the solution is clear the hydroxyethyl cellulose is added and mixed until gelation is complete. Gel B was made by dissolving iodide in a water/propylene glycol mix. Hydroxyethyl cellulose was added to this mixture and mixed until gelation was complete.

15

The gels were packaged in separate syringes which were bound together with their nozzles fitted into a Y-shaped connector. The contents were sterilised by autoclaving at 121 C for 15 minutes. Simultaneous depression of the plungers allows the gels to be co-extruded and allows the gels to react while being dispensed into a wound. The co-extrusion of the gels results in a product producing approximately 100µg per g of composition per hour at a pH of about 5.4. The composition generated a greater than 5 log kill of *S. aureus* (NCIMB 9518) which is regarded as being an acceptable level of antimicrobial activity.

20

#### Example 2

#### Film A

g

CV0290

-7-

Hydroxypropylcellulose	16
Propylene Glycol	4
Potassium Iodate	0.1124
Sodium phosphate	1.7805
5 Citric acid	1.0505
Water	77.0566

Film B

Hydroxypropylcellulose	16
10 Propylene Glycol	4
Potassium Iodide	0.436
Water	79.564

15 The films are produced by knife over roller coating of aqueous solution onto an inert carrier followed by drying at a temperature not exceeding 100 C and sterilised by gamma irradiation.

The films may be cut into rectangles and added to a wound whereupon they dissolve in the wound fluid and reaction takes place.

CV0290

-8-

Claims

1. An iodine preparation composition suitable for use on wounds comprising an iodide source, and oxidant and a buffer characterised in that the iodide is held separately from the oxidant until the point of use, and that the buffer is capable of maintaining the pH of the composition at between pH 4.5 and pH 6 so that iodine is generated at a physiologically acceptable dose and rate.

2. An iodine preparation composition suitable for use on wounds comprising an iodide source, an oxidant and a buffer for simultaneous or sequential use in the treatment of sepsis in wounds.

3. Use of an iodine preparation composition comprising an iodide source, an oxidant and a buffer for simultaneous or sequential use in the treatment of sepsis in wounds.

4. An iodine preparation composition as claimed in claim 1 characterised in that the composition is capable of generating from 5µg of iodine per g of composition per hour to 1500µg of iodine per g of composition per hour, preferably 100µg of iodine per g of composition per hour.